Melittin
Anti-Inflammatory / ResearchAlso known as: Bee Venom Peptide, Apis Mellifera Venom Peptide
Mechanism
The main active ingredient in bee venom, making up about half of dry bee venom by weight. While bee stings hurt because melittin destroys cell membranes, researchers have found that at controlled doses it has powerful anti-inflammatory, anti-cancer, and antimicrobial effects. Bee venom therapy (apitherapy) — used for centuries for arthritis and pain — works largely because of melittin.
Technical detail
26-amino-acid amphipathic alpha-helical peptide (GIGAVLKVLTTGLPALISWIKRKRQQ) comprising approximately 50% of dry Apis mellifera venom. Primary mechanism is membrane disruption via a detergent-like toroidal pore model, with selectivity influenced by membrane cholesterol content. Potent phospholipase A2 (PLA2) activator, releasing arachidonic acid and driving prostaglandin synthesis. Paradoxical anti-inflammatory effects at sub-lytic concentrations: inhibits NF-kB nuclear translocation, suppresses cyclooxygenase-2 (COX-2) expression, and reduces TNF-alpha and IL-1beta in macrophages. Anti-cancer activity demonstrated via induction of apoptosis through PLA2-dependent cytochrome c release. Being engineered as nanoparticle-delivered anti-cancer agent (e.g., melittin-loaded perfluorocarbon nanoparticles).
Effects
MUSCULOSKELETAL SYSTEM: Potent anti-inflammatory via paradoxical mechanism — melittin activates phospholipase A2 (PLA2), releasing arachidonic acid which is then shunted toward pro-resolving lipid mediators (lipoxins, resolvins) rather than pro-inflammatory prostaglandins at therapeutic doses [animal studies, in vitro]. Significant pain reduction in osteoarthritis and rheumatoid arthritis models through suppression of NF-κB signaling and COX-2 expression [RCT — Park et al., 2004; multiple Korean medicine RCTs]. IMMUNE SYSTEM: Dual immunomodulatory action — low doses suppress inflammatory cytokines (TNF-α, IL-1β, IL-6) while activating regulatory T-cell pathways; high doses trigger massive mast cell degranulation and anaphylaxis [animal, clinical observation]. NERVOUS SYSTEM: Investigated for multiple sclerosis via suppression of neuroinflammation and demyelination in EAE mouse models [animal]. Bee venom therapy (BVT) practitioners report symptomatic improvement in MS patients, though controlled trial data is limited [case reports, practitioner protocols]. ONCOLOGY: Membrane-lytic activity against tumor cells — melittin's amphipathic α-helical structure preferentially disrupts cancer cell membranes (higher negative charge vs. normal cells), inducing necrosis and apoptosis [in vitro, animal]. Nanoparticle-delivered melittin (nanobees) showed tumor regression in murine breast cancer and melanoma models [animal — Soman et al., 2009]. ANTIMICROBIAL: Broad-spectrum activity against gram-positive and gram-negative bacteria, fungi, and some enveloped viruses through membrane disruption [in vitro]. CARDIOVASCULAR: At toxic doses, severe hemolysis due to red blood cell membrane disruption — the primary danger of systemic administration [in vitro, case reports]. Cardiotoxicity reported at high doses including arrhythmia [animal, case reports].
Practitioner Guide
ADMINISTRATION: Bee venom therapy (BVT) is the traditional delivery — live bee stings or purified bee venom injections at acupuncture points. Korean medicine protocol: start with sensitivity test (single sting on forearm, observe 20 min for anaphylaxis), then 2-5 sting sites per session at affected joints, 2-3x/week. Naturopathic protocol: purified bee venom (apitoxin) 0.1-1.0mg injected subcutaneously at pain sites. Some practitioners use bee venom acupuncture (BVA) — 0.05-0.1mL of diluted venom per acupoint. CRITICAL SAFETY: Always have epinephrine auto-injector available. Allergy testing mandatory before first session. Anaphylaxis risk is real and potentially fatal — estimated 1-2% of population has bee venom allergy. Repeated exposure can sensitize patients who were previously tolerant. NEVER use systemically (IV) — hemolytic and cardiotoxic. CYCLING: Korean BVT protocols typically run 8-12 weeks for arthritis, with 4-week breaks. Some practitioners do maintenance 1x/week indefinitely. STACKING: Often combined with acupuncture, curcumin (1-2g/day oral), and omega-3 fatty acids to enhance the pro-resolving lipid mediator pathway. STORAGE: Purified bee venom solutions stored at 2-8°C, protect from light. Lyophilized venom stable at room temperature. COMPOUNDING: Some compounding pharmacies prepare standardized bee venom solutions (typically 0.1mg/mL in saline) for injection. Quality varies significantly — source matters. CONTRAINDICATIONS: Bee venom allergy, autoimmune conditions in flare (can worsen), pregnancy, severe cardiac disease, patients on beta-blockers (may blunt epinephrine response in anaphylaxis). MONITORING: Watch for delayed hypersensitivity reactions (24-48h post-treatment), progressive local swelling, or systemic symptoms (urticaria, dyspnea).
Research Summary
TIER 1: Multiple RCTs on bee venom acupuncture for osteoarthritis (Park et al., 2004 — significant pain reduction vs. saline; Lee et al., 2012 — improvement in WOMAC scores). Korean medicine RCTs for rheumatoid arthritis showing reduced morning stiffness and joint swelling. No FDA-approved melittin therapeutics. TIER 2: Systematic reviews of BVT for musculoskeletal pain (Zhang et al., 2018 — moderate evidence for OA, weak for RA). Preclinical reviews on melittin-loaded nanoparticles for cancer therapy. Comprehensive review of melittin antimicrobial mechanisms (Memariani et al., 2020). TIER 3: Korean medicine case series for MS treatment with BVT (symptom improvement in small cohorts). Practitioner reports from naturopathic BVT clinics documenting arthritis remission. International data from apitherapy societies (anecdotal, poorly controlled). KEY FINDINGS: Melittin is a legitimate anti-inflammatory with a unique mechanism, but the therapeutic window is narrow — effective doses are close to toxic doses. Nanoparticle delivery may solve the toxicity problem for cancer applications. BVT is the only practical clinical application currently. GAPS: No large multicenter RCTs for any indication. No standardized dosing protocols. Nanoparticle delivery still preclinical. Long-term safety of repeated BVT unknown. ACTIVE TRIALS: Several Korean RCTs ongoing for BVT in knee osteoarthritis and low back pain. Early-phase work on melittin-conjugated nanoparticles for solid tumors.